cancer drug
-
Lixte’s Big Bet: Making Other Cancer Drugs Work Harder
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) is a Nasdaq-listed biotech with an unusually focused story: one main drug,…
-
Valeo Pharma’s approval and launch of immune support product line Redesca and Redesca HP anticipated to impact first half 2021 revenue
Most investors know that the pharmaceutical industry is a huge and mostly very profitable industry. What they may…
